Squarepoint’s Catheter Precision VTAK Stock Holding History

Squarepoint’s Portfolio VTAK Stock Details VTAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	-$80K	–	3736
2021 Q1	$80K	Hold	2	–	–	﹤0.01%	2946
2020 Q4	$117K	Buy	+2	New	+$119K	﹤0.01%	2685

Other funds holding VTAK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint's VTAK Position: Q2 2021 in Review

Squarepoint sold out of Catheter Precision (VTAK) in Q2 2021, closing a stake of 2 shares — an estimated $80K sold.

Squarepoint first reported a position in VTAK in Q4 2020 and held it in 2 quarters. The position peaked at $117K in Q4 2020. 10 funds tracked by Wall St. Rank hold VTAK as of Q2 2021.

Squarepoint reported no remaining Catheter Precision position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 2 Catheter Precision shares in Q2 2021, an estimated $80K.
Squarepoint first reported a position in Catheter Precision in Q4 2020 and held it in 2 quarters.
Squarepoint's Catheter Precision position peaked at $117K in Q4 2020.
10 funds tracked by Wall St. Rank held Catheter Precision as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.